Fortress Biotech Inc reports results for the quarter ended December 31 - Earnings Summary

• Fortress Biotech Inc FBIO.OQ reported a quarterly adjusted loss of 75 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of $-1.28. The mean expectation of three analysts for the quarter was for a loss of 75 cents per share. Wall Street expected results to range from -83 cents to -68 cents per share.

• Revenue fell 24.2% to $15.12 million from a year ago; analysts expected $16.30 million.

• Fortress Biotech Inc's reported EPS for the quarter was a loss of 26 cents​.

• The company reported a quarterly loss of $9.65 million.

• Fortress Biotech Inc shares had fallen by 20.5% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts was unchanged in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

• Wall Street's median 12-month price target for Fortress Biotech Inc is $16.00

This summary was machine generated from LSEG data March 31 at 09:00 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)